Therefore, we particularly focused on sunitinib resistance and performed immunohistochemical experiments on tumor samples to validate the discriminatory potential of four new candidate biomarkers, LGALS8, RAB17, EpCAM, and CD9. This evidence concerns the gene EPCAM and neoplasm.